Company intelligence / Profile preview
ImmunoChem Therapeutics
- Ownership
- Private
- Employees
- ~9
- Development stage
- Preclinical
Overview
ImmunoChem Therapeutics is a clinical-stage biotech developing brain-specific, small molecule drugs to block neuroinflammation. Their lead candidate, MW189, is in an NIH-funded proof-of-concept Phase 2a trial for intracerebral hemorrhage. The company’s strategy is to first target orphan CNS diseases as a fast path to market and then expand into broader neurodegenerative indications such as Alzheimer’s disease. Clinical results are pending from ongoing trials.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on ImmunoChem Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmunoChem Therapeutics.